Estimated Human Absorbed Dose of 111In-BPAMD as a New Bone-Seeking SPECT-Imaging Agent

Authors: H. Yousefnia, S. Zolghadri

Abstract:

An early diagnosis of bone metastasis is very important for making a right decision on a subsequent therapy. One of the most important steps to be taken initially, for developing a new radiopharmaceutical is the measurement of organ radiation exposure dose. In this study, the dosimetric studies of a novel agent for SPECT-imaging of the bone metastasis, 111In-(4- {[(bis(phosphonomethyl))carbamoyl]methyl}7,10bis(carboxymethyl) -1,4,7,10-tetraazacyclododec-1-yl) acetic acid (111In-BPAMD) complex, have been carried out to estimate the dose in human organs based on the data derived from mice. The radiolabeled complex was prepared with high radiochemical purity in the optimal conditions. Biodistribution studies of the complex was investigated in the male Syrian mice at the selected times after injection (2, 4, 24 and 48 h). The human absorbed dose estimation of the complex was made based on data derived from the mice by the radiation absorbed dose assessment resource (RADAR) method. 111In-BPAMD complex was prepared with high radiochemical purity >95% (ITLC) and specific activities of 2.85 TBq/mmol. Total body effective absorbed dose for 111In-BPAMD was 0.205 mSv/MBq. This value is comparable to the other 111In clinically used complexes. The results show that the dose with respect to the critical organs is satisfactory within the acceptable range for diagnostic nuclear medicine procedures. Generally, 111In-BPAMD has interesting characteristics and it can be considered as a viable agent for SPECT-imaging of the bone metastasis in the near future.

Keywords: In-111, BPAMD, absorbed dose, RADAR.

Digital Object Identifier (DOI): doi.org/10.5281/zenodo.1109860

References:

[1] IAEA-TECDOC-1549, “Criteria for Palliation of Bone Metastases- Clinical Applications,”. Austria, Vienna: IAEA; 2007.
[2] A. Lipton, “Pathophysiology of Bone Metastases: How This Knowledge May Lead to Therapeutic Intervention,” J. Support. Oncol. vol. 2, pp. 205-20, 2004.
[3] M. Fellner, B. Biesalski, N. Bausbacher, V. Kubícek, P. Hermann, F. Rösch, O. Thews, “68Ga-BPAMD: PET-imaging of bone metastases with a generator based positron emitter,” Nucl. Med. Biol. vol. 39, pp. 993–9, 2012.
[4] G. Zettinig, T. Leitha, B. Niederle, K. Kaserer, A. Becherer, K. Kletter. et al. “FDG positron emission tomographic, radioiodine, and MIBI imaging in a patient with poorly differentiated insular thyroid carcinoma,” Clin. Nucl. Med. Vol. 26, pp. 599–601, 2001.
[5] H. Yousefnia, A.R. Jalilian, S. Zolghadri, A. Mirzaei, A. Bahrami- Samani, M. Mirzaii, M. Ghannadi, “Development of 111In DOTMP for dosimetry of bone pain palliation agents,” J. Radioanal. Nucl. Chem. DOI 10.1007/s10967-014-3911-6.
[6] M. Fellner, R.P. Baum, V. Kubícek, P. Hermann, I. Lukeš, V. Prasad et al., “PET/CT imaging of osteoblastic bone metastases with 68Gabisphosphonates: first human study,” Eur. J. Nucl. Med. Mol. Imaging, vol. 37, pp. 834, 2010.
[7] J. Lai, S.M. Quadri, P.E. Borchardt, L. Harris , R. Wucher , E. Askew et al., “Pharmaco-kinetics of radiolabeled polyclonal antiferritin in patients with Hodgkin’s disease,” Clin. Cancer Res, vol. 5, pp. 3315−23, 1999.
[8] M.W. Nijhof, W.J. Oyen, A. Van Kampen, R.A. Claessens, J.W. Van der Meer, F.H. Corstens, “Evaluation of infections of the locomotor system with indium-111-labeled human IgG scintigraphy,” J. Nucl. Med., vol. 38, pp. 1300−05, 1997.
[9] M.G. Stabin, M. Tagesson, S.R. Thomas, M. Ljungberg , S.E .Strand, “Radiation dosimetry in nuclear medicine,” Appl. Radiat. Isot., vol. 50, pp. 73-87, 1996.
[10] M.G. Stabin, “Internal Dosimetry in Nuclear Medicine,” Braz. J. Radiat. Sci., vol. 01, pp. 1-15, 2013.
[11] M.G. Stabin, J.A. Siegel, “Physical Models and Dose Factors for Use in Internal Dose Assessment,” Health. Phys., vol. 85, pp. 294-310, 2003.
[12] IAEA-TECDOC-1401, “Quantifying uncertainty in nuclear analytical measurements,” Austria, Vienna: IAEA; 2004.
[13] R.B. Sparks, B. Aydogan, “Comparison of the effectiveness of some common animal data scaling techniques in estimating human radiation dose,” Sixth International Radiopharmaceutical Dosimetry Symposium, Oak Ridge, TN: Oak Ridge Associated Universities, pp. 705–16, 1996.
[14] H. Yousefnia, S. Zolghadri, A.R. Jalilian, M. Tajik, M. Ghannadi- Maragheh, “Preliminary dosimetric evaluation of 166Ho-TTHMP for human based on biodistribution data in rats,” Appl. Radiat. Isot., vol. 94, pp. 260-5, 2014.
[15] J.J. Bevelacqua, “Internal dosimetry primer,” Radiat. Prot. Manage., vol. 22, pp. 7-17, 2005.
[16] D.J. Brenner, “Effective dose: a flawed concept that could and should be replaced,” British. J. Radiol., vol. 81, pp. 521–3, 2008.
[17] ICRP Publication 103, “The 2007 Recommendations of the International Commission on Radiological Protection,” Ann. ICRP, vol. 37, pp. 2-4, 2007.
[18] United States Pharmacopoeia 28, NF 23, pp. 1009, 2005.
[19] J.T. Bushberg, J.A. Seibert, E.M. Leidholdt, J.M. Boone, “The Essential Physics of Medical Imaging,” Third Edition, Lippincott Williams & Wilkins; 2011.
[20] C. Muller, R. Schibli, “Single Photon Emission Computed Tomography Tracer,” Mol. Imaging Oncol., vol. 187, pp. 65-105. 2013.
[21] A.L. Kesner, W.A. Hsueh, J. Czernin, H. Padgett, M.E. Phelps, D.H. Silverman, “Radiation dose estimates for (18F)5-fluorouracil derived from PET-based and tissue-based methods in rats,” Mol. Imaging Biol., vol. 10, pp. 341-8, 2008.
[22] ICRP Publication 62, “Radiological Protection in Biomedical Research,” Ann. ICRP, vol. 22, pp. 3, 1993.
[23] ICRP Publication 53, “Radiation Dose to Patients from Radiopharmaceuticals,” Ann. ICRP, vol. 18, pp. 1-4, 1988.
[24] Radiation Internal Dose Information Center, “Radiation dose estimates to adults and children from various radiopharmaceuticals,” Oak Ridge Institute for Science and Education. Oak Ridge, TN 37831. Available at: orise.orau.gov/files/reacts/pedose.pdf.